Flamel Technologies S.A. (ADR) (NASDAQ:FLML)
A biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
I'll be the first to admit that I don't understand this wiggly, opaque little biopharma but somehow I keep scoring on my picks in both directions. Ten wins so far without a miss and this is my lowest green thumb entry yet. I don't have the slightest explanation for the substantial volatility in the stock over the last year, but the share price has rocketed upward twice from this level and I don't see any reason for the current plunge. Maybe a submission of an NDA for an unidentified product later this quarter will catalyze a change in momentum.
Recs
There are currently 450 FLML shares in my "fund" with break-even of around 4.82 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Recs
nanobiotech good technicals
Recs
No new drugs for a long time....
Recs
nano!
Recs
5.1172 at $111.00 or 21.69 per share. Can't do much worse.
Recs
Niche in medical technology will pay off.
Recs
THIS STOCK HAS BEEN AT $31.96, BELIEVE ITS ON ITS WAY TO THAT AREA AGAIN
Recs
Never stays above 30, but surely gets there every now and then, so at a price below 10, this is a good bargain.
Recs
Drug release procall for insulin
Recs
Bought at the bottom of their 52 week range. Not sure even that price is justified, but hoping their delivery technology will find new markets.
Recs
purely a play on the fallen who should get up, even if its to a crawling position....
Recs
Recs
New license with Wyeth for the use of its protein delivery system.
Recs
Powerful technology, activist investors, and 52-low price adds up to a market over-reaction. Buy now sit back, and enjoy the ride. This will return at least 50% in the next year or so.
Recs
The French are now our friends.
Recs
Negative news at Glaxo has this name oversold. At today's price, I think this will outperform.
Recs
badly beaten up!
Recs
I think this is about as low as it will get.
Recs
Coreg CR is slow on the pick up, but it will eventually be the primary version of Coreg prescribed. The first quarter numbers of sales were slow, so the stock has pulled back, ready to spring even further!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 50 : 1 2 3 Next »